Stock Analiz

IDEXX Laboratories Inc. (IDXX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

IDEXX Laboratories’s revenue went from $1.8B in fiscal 2016 to $4.3B in fiscal 2025, growth of about 10.3% a year.

Net income in fiscal 2025 was $1.1B, a net margin of 24.6%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $4.7B and net income $1.2B.

Free cash flow was $1.1B in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count fell 11% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $1.8B162017: $2.0B172018: $2.2B182019: $2.4B192020: $2.7B202021: $3.2B212022: $3.4B222023: $3.7B232024: $3.9B242025: $4.3B25$4.3B
Net income
2016: $222M162017: $263M172018: $377M182019: $428M192020: $582M202021: $745M212022: $679M222023: $845M232024: $888M242025: $1.1B25$1.1B
Free cash flow
2016: $274M162017: $299M172018: $284M182019: $304M192020: $541M202021: $636M212022: $394M222023: $773M232024: $808M242025: $1.1B25$1.1B
EPS (diluted)
2016: $2.44162017: $2.94172018: $4.26182019: $4.89192020: $6.71202021: $8.60212022: $8.03222023: $10.06232024: $10.67242025: $13.0825$13.08

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$4.7B$4.3B$3.9B$3.7B$3.4B$3.2B$2.7B$2.4B$2.2B$2.0B$1.8B
Gross profit$2.9B$2.7B$2.4B$2.2B$2.0B$1.9B$1.6B$1.4B$1.2B$1.1B$975M
Operating income$1.5B$1.4B$1.1B$1.1B$899M$932M$695M$553M$491M$413M$350M
Net income$1.2B$1.1B$888M$845M$679M$745M$582M$428M$377M$263M$222M
EPS (diluted)$14.84$13.08$10.67$10.06$8.03$8.60$6.71$4.89$4.26$2.94$2.44
R&D$267M$251M$220M$191M$255M$161M$141M$133M$118M$109M$101M
Revenue growth—+10.4%+6.5%+8.7%+4.7%+18.8%+12.4%+8.8%+12.4%+10.9%+10.8%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$1.4B$1.2B$929M$907M$543M$756M$648M$459M$400M$373M$339M
Capital spending-$115M-$125M-$121M-$134M-$149M-$120M-$107M-$155M-$116M-$74M-$65M
Free cash flow$1.3B$1.1B$808M$773M$394M$636M$541M$304M$284M$299M$274M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$1.0B$1.2B$837M$72M$820M$747M$183M$302M$369M$283M$304M
Stock-based pay$65M$60M$60M$60M$50M$38M$31M$39M$25M$24M$20M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$180M$288M$454M$113M$144M$384M$90M$124M$472M$392M
Debt—$578M$737M$818M$891M$958M$1.0B$782M$1.0B$1.3B$1.2B
Equity—$1.6B$1.6B$1.5B$609M$690M$632M$177M-$10M-$54M-$108M
Total assets—$3.4B$3.3B$3.3B$2.7B$2.4B$2.3B$1.8B$1.5B$1.7B$1.5B
Shares (diluted)79M81M83M84M85M87M87M88M88M90M91M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin62.7%61.8%61.0%59.8%59.5%58.8%58.0%56.7%56.1%55.7%54.9%
Operating margin32.3%31.6%28.9%30.0%26.7%29.0%25.7%23.0%22.2%21.0%19.7%
Net margin25.4%24.6%22.8%23.1%20.2%23.2%21.5%17.8%17.0%13.4%12.5%
FCF margin28.0%24.6%20.7%21.1%11.7%19.8%20.0%12.6%12.8%15.2%15.4%
ROIC—49.8%38.7%38.0%47.3%46.7%37.3%47.2%40.8%23.6%22.1%
ROE—66.0%55.6%56.9%111.6%107.9%92.0%241.0%-3963.3%-486.4%-204.9%

Frequently asked questions

What is IDEXX Laboratories’s annual revenue?

$4.3B in fiscal 2025 and $4.7B over the twelve months to September 30, 2026.

How much profit does IDEXX Laboratories make?

Net income was $1.1B in fiscal 2025 (net margin 24.6%).

Is IDEXX Laboratories’s revenue growing?

Yes: revenue rose 10.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.